摘要
目的探讨参七脉心通胶囊对经皮冠脉介入术后患者支架内再狭窄及炎症因子的影响。方法选取2021年12月至2023年1月广州市中西医结合医院收治的60例冠心病介入术后患者作为研究对象,按照随机数字表法分为对照组和试验组各30例。对照组予以指南推荐标准药物治疗方案,试验组则在标准治疗基础上加用参七脉心通胶囊(4粒,tid),疗程24周。治疗后进行中医证候疗效评价、观察支架内再狭窄及支架内血栓情况,测定血清基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)及肿瘤坏死因子(TNF-α)水平。结果治疗后,试验组中医证候疗效及积分均高于对照组,差异有统计学意义(P<0.05);支架内再狭窄发生率低于对照组,差异有统计学意义(P<0.05);两组支架内血栓情况比较,差异无统计学意义(P>0.05);试验组血清MMP、IL-6、IL-8、TNF-α的水平低于对照组,差异有统计学意义(P<0.05)。结论参七脉心通胶囊可通过降低患者血清MMP-9、IL-6、IL-8及TNF-α的水平,从而有效抑制内皮细胞炎症反应,降低支架内再狭窄率、改善临床症状。
Objective To investigate the effect of Shenqi Maixintong(SQMXT)Capsules on in-stent restenosis(ISR)and inflammatory factors in patients after percutaneous coronary intervention(PCI).Methods A total of 60 patients with coronary heart disease after PCI in Guangzhou Hospital of Integrated Traditional and Western Medicine from December 2021 to January 2023 were selected as the study objects and they were divided into control group and experimental group according to the random number table method,with 30 cases in each group.The control group was treated with the standard drug regimen recommended by the guidelines,and the experimental group was treated with SQMXT Capsules(4 capsules,tid)on the basis of the standard treatment for 24 weeks.After treatment,the traditional chinese medicine(TCM)syndrome efficacy was evaluated,the ISR and in-stent thrombosis were observed,and the serum levels of matrix metalloproteinase-9(MMP-9),interleukin-6(IL-6),interleukin-8(IL-8)and tumor necrosis factor(TNF-α)were measured.Results After treatment,the efficacy and score of TCM syndrome in the experimental group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the incidence of in-stent restenosis was lower than that of the control group,and the difference was statistically significant(P<0.05).After treatment,there was no significant difference in stent thrombosis between the two groups(P>0.05).After treatment,the serum levels of MMP,IL-6,IL-8,and TNF-αin the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion SQMXT Capsule can effectively inhibit the inflammatory response of endothelial cells,reduce the rate of ISR and improve the clinical symptoms by reducing the serum levels of MMP-9,IL-6,IL-8 and TNF-α.
作者
王锐
吴永刚
聂鹏飞
李幸洲
郑舒馨
侯燕青
WANG Rui;WU Yonggang;NIE Pengfei;LI Xingzhou;ZHENG Shuxin;HOU Yanqing(Department of Cardiology,Guangzhou Hospital of Integrated Chinese and Western Medicine,Guangdong Province,Guangzhou510800,China)
出处
《中国当代医药》
CAS
2024年第10期66-70,共5页
China Modern Medicine
基金
广东省中医药局课题(20231257)
广东省广州市花都区科技计划项目(21-HDWS-080)。
关键词
参七脉心通胶囊
冠心病
经皮冠脉介入术
支架内再狭窄
Shenqi Maixintong Capsules
Coronary heart disease
Percutaneous coronary intervention
In-stent restenosis
